Feng Q, Tang LJ, Luo DH, et al. - Metabolic syndrome (MetS)-related hyperuricemia holds prognostic importance on survival in colorectal cancer (CRC).

• A correlation of hyperuricemia and MetS with the prognosis in malignant tumors has been reported.

• A total of 1,271 patients who had undergone radical CRC resection were included and were preoperatively split into four groups: those with hyperuricemia alone (H), those with MetS alone (MS), those with MetS-related hyperuricemia (MSH), and those with neither condition (control [C] group).

• Significant link between preoperative MetS and hyperuricemia was found.

• In multivariate Cox regression analysis, MetS-related hyperuricemia (hazard ratio [HR] = 2.728) as well as MetS alone (HR = 1.631) were identified as independent predictors of death, whereas simple hyperuricemia was not.

• Compared with the C group, the highest rate of tumor recurrence or metastasis was observed in the MSH group (HR = 5.103), followed by the MS (HR = 2.231) group.

• There was a significant link of MetS with poor prognosis, with MetS-related hyperuricemia causing a significantly poorer prognosis.

• In contrast, long-term prognosis remained unaffected by hyperuricemia alone.